Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 46

1.

Genetic and epigenetic alterations in the tumour, tumour margins, and normal buccal mucosa of patients with oral cancer.

Eljabo N, Nikolic N, Carkic J, Jelovac D, Lazarevic M, Tanic N, Milasin J.

Int J Oral Maxillofac Surg. 2018 Aug;47(8):976-982. doi: 10.1016/j.ijom.2018.01.020. Epub 2018 Feb 12.

PMID:
29449053
2.

TNF-α (-308G>A) and TNF-R1 (36A>G) single nucleotide polymorphisms are strong risk factors for odontogenic keratocystic tumor development.

Ilic B, Nikolic N, Andric M, Jelovac D, Milicic B, Jozic T, Krstic S, Milasin J.

J Oral Pathol Med. 2017 Apr;46(4):292-296. doi: 10.1111/jop.12564. Epub 2017 Mar 5.

PMID:
28199753
3.

A phase I trial of paclitaxel, cisplatin, and veliparib in the treatment of persistent or recurrent carcinoma of the cervix: an NRG Oncology Study (NCT#01281852).

Thaker PH, Salani R, Brady WE, Lankes HA, Cohn DE, Mutch DG, Mannel RS, Bell-McGuinn KM, Di Silvestro PA, Jelovac D, Carter JS, Duan W, Resnick KE, Dizon DS, Aghajanian C, Fracasso PM.

Ann Oncol. 2017 Mar 1;28(3):505-511. doi: 10.1093/annonc/mdw635.

4.

Prevalence of chemopreventive agent use among hospitalised women at high risk for breast cancer: a cross-sectional study.

Khaliq W, Jelovac D, Wright SM.

BMJ Open. 2016 Nov 16;6(11):e012550. doi: 10.1136/bmjopen-2016-012550.

5.

Modified Risdon approach using periangular incision in surgical treatment of subcondylar mandibular fractures.

Nikolić ŽS, Jelovac DB, Šabani M, Jeremić JV.

Srp Arh Celok Lek. 2016 Jul-Aug;144(7-8):391-6.

PMID:
29652446
6.

Impact of the lower third molar and injury mechanism on the risk of mandibular angle and condylar fractures.

Antic S, Milicic B, Jelovac DB, Djuric M.

Dent Traumatol. 2016 Aug;32(4):286-95. doi: 10.1111/edt.12259. Epub 2016 Jan 28.

PMID:
26821987
7.

The amplification of c-erb-B2 in cancer-free surgical margins is a predictor of poor outcome in oral squamous cell carcinoma.

Jelovac DB, Tepavčević Z, Nikolić N, Ilić B, Eljabo N, Popović B, Čarkić J, Konstantinović V, Vukadinović M, Miličić B, Milašin J.

Int J Oral Maxillofac Surg. 2016 Jun;45(6):700-5. doi: 10.1016/j.ijom.2015.11.014. Epub 2015 Dec 18.

PMID:
26708050
8.

Phase 1b safety study of farletuzumab, carboplatin and pegylated liposomal doxorubicin in patients with platinum-sensitive epithelial ovarian cancer.

Kim KH, Jelovac D, Armstrong DK, Schwartz B, Weil SC, Schweizer C, Alvarez RD.

Gynecol Oncol. 2016 Feb;140(2):210-4. doi: 10.1016/j.ygyno.2015.11.031. Epub 2015 Nov 28.

9.

Emerging immunotherapies in ovarian cancer.

Ojalvo LS, Nichols PE, Jelovac D, Emens LA.

Discov Med. 2015 Sep;20(109):97-109. Review.

10.

Osteonecrosis of the jaw as a serious adverse effect of bisphosphonate therapy and its indistinct etiopathogenesis.

Gavrić M, Antić S, Jelovac DB, Zarev AI, Petrović MB, Golubović M, Antunović M.

Vojnosanit Pregl. 2014 Aug;71(8):772-6. Review. No abstract available.

PMID:
25181838
11.

Detection of cancer DNA in plasma of patients with early-stage breast cancer.

Beaver JA, Jelovac D, Balukrishna S, Cochran R, Croessmann S, Zabransky DJ, Wong HY, Toro PV, Cidado J, Blair BG, Chu D, Burns T, Higgins MJ, Stearns V, Jacobs L, Habibi M, Lange J, Hurley PJ, Lauring J, VanDenBerg D, Kessler J, Jeter S, Samuels ML, Maar D, Cope L, Cimino-Mathews A, Argani P, Wolff AC, Park BH.

Clin Cancer Res. 2014 May 15;20(10):2643-2650. doi: 10.1158/1078-0432.CCR-13-2933. Epub 2014 Feb 6.

12.

A PIK3CA mutation detected in plasma from a patient with synchronous primary breast and lung cancers.

Jelovac D, Beaver JA, Balukrishna S, Wong HY, Toro PV, Cimino-Mathews A, Argani P, Stearns V, Jacobs L, VanDenBerg D, Kessler J, Jeter S, Park BH, Wolff AC.

Hum Pathol. 2014 Apr;45(4):880-3. doi: 10.1016/j.humpath.2013.10.016. Epub 2013 Oct 31.

13.

Treatment of HER2-positive breast cancer.

Figueroa-Magalhães MC, Jelovac D, Connolly R, Wolff AC.

Breast. 2014 Apr;23(2):128-136. doi: 10.1016/j.breast.2013.11.011. Epub 2013 Dec 19. Review.

14.

HER2-directed therapy for metastatic breast cancer.

Jelovac D, Emens LA.

Oncology (Williston Park). 2013 Mar;27(3):166-75. Review.

15.

Single copies of mutant KRAS and mutant PIK3CA cooperate in immortalized human epithelial cells to induce tumor formation.

Wang GM, Wong HY, Konishi H, Blair BG, Abukhdeir AM, Gustin JP, Rosen DM, Denmeade SR, Rasheed Z, Matsui W, Garay JP, Mohseni M, Higgins MJ, Cidado J, Jelovac D, Croessmann S, Cochran RL, Karnan S, Konishi Y, Ota A, Hosokawa Y, Argani P, Lauring J, Park BH.

Cancer Res. 2013 Jun 1;73(11):3248-61. doi: 10.1158/0008-5472.CAN-12-1578. Epub 2013 Apr 11.

16.

Malignant ameloblastoma metastasis to the neck--radiological and pathohistological dilemma.

Golubović M, Petrović M, Jelovac DB, Nenezić DU, Antunović M.

Vojnosanit Pregl. 2012 May;69(5):444-8.

PMID:
22764549
17.

Role of farletuzumab in epithelial ovarian carcinoma.

Jelovac D, Armstrong DK.

Curr Pharm Des. 2012;18(25):3812-5.

18.

Detection of tumor PIK3CA status in metastatic breast cancer using peripheral blood.

Higgins MJ, Jelovac D, Barnathan E, Blair B, Slater S, Powers P, Zorzi J, Jeter SC, Oliver GR, Fetting J, Emens L, Riley C, Stearns V, Diehl F, Angenendt P, Huang P, Cope L, Argani P, Murphy KM, Bachman KE, Greshock J, Wolff AC, Park BH.

Clin Cancer Res. 2012 Jun 15;18(12):3462-9. doi: 10.1158/1078-0432.CCR-11-2696. Epub 2012 Mar 15.

19.

The adjuvant treatment of HER2-positive breast cancer.

Jelovac D, Wolff AC.

Curr Treat Options Oncol. 2012 Jun;13(2):230-9. doi: 10.1007/s11864-012-0186-4. Review.

PMID:
22410709
20.

The growth response to androgen receptor signaling in ERα-negative human breast cells is dependent on p21 and mediated by MAPK activation.

Garay JP, Karakas B, Abukhdeir AM, Cosgrove DP, Gustin JP, Higgins MJ, Konishi H, Konishi Y, Lauring J, Mohseni M, Wang GM, Jelovac D, Weeraratna A, Sherman Baust CA, Morin PJ, Toubaji A, Meeker A, De Marzo AM, Lewis G, Subhawong A, Argani P, Park BH.

Breast Cancer Res. 2012 Feb 9;14(1):R27.

21.

Intraperitoneal treatment in ovarian cancer: the gynecologic oncology group perspective in 2012.

Armstrong DK, Fujiwara K, Jelovac D.

Am Soc Clin Oncol Educ Book. 2012:345-8. doi: 10.14694/EdBook_AM.2012.32.345.

22.

Mutation of a single allele of the cancer susceptibility gene BRCA1 leads to genomic instability in human breast epithelial cells.

Konishi H, Mohseni M, Tamaki A, Garay JP, Croessmann S, Karnan S, Ota A, Wong HY, Konishi Y, Karakas B, Tahir K, Abukhdeir AM, Gustin JP, Cidado J, Wang GM, Cosgrove D, Cochran R, Jelovac D, Higgins MJ, Arena S, Hawkins L, Lauring J, Gross AL, Heaphy CM, Hosokawa Y, Gabrielson E, Meeker AK, Visvanathan K, Argani P, Bachman KE, Park BH.

Proc Natl Acad Sci U S A. 2011 Oct 25;108(43):17773-8. doi: 10.1073/pnas.1110969108. Epub 2011 Oct 10.

23.

Recent progress in the diagnosis and treatment of ovarian cancer.

Jelovac D, Armstrong DK.

CA Cancer J Clin. 2011 May-Jun;61(3):183-203. doi: 10.3322/caac.20113. Epub 2011 Apr 26.

24.

PTEN promoter silencing and Cowden syndrome: the role of epigenetic regulation of KILLIN.

Jelovac D, Park BH.

JAMA. 2010 Dec 22;304(24):2744-5. doi: 10.1001/jama.2010.1863. No abstract available.

PMID:
21177512
25.

PIK3CA mutations and EGFR overexpression predict for lithium sensitivity in human breast epithelial cells.

Higgins MJ, Beaver JA, Wong HY, Gustin JP, Lauring JD, Garay JP, Konishi H, Mohseni M, Wang GM, Cidado J, Jelovac D, Cosgrove DP, Tamaki A, Abukhdeir AM, Park BH.

Cancer Biol Ther. 2011 Feb 1;11(3):358-67. Epub 2011 Feb 1.

26.

Oral squamous cell carcinoma detection by salivary biomarkers in a Serbian population.

Brinkmann O, Kastratovic DA, Dimitrijevic MV, Konstantinovic VS, Jelovac DB, Antic J, Nesic VS, Markovic SZ, Martinovic ZR, Akin D, Spielmann N, Zhou H, Wong DT.

Oral Oncol. 2011 Jan;47(1):51-5. doi: 10.1016/j.oraloncology.2010.10.009. Epub 2010 Nov 24.

27.

Epidemiological, clinical, and forensic aspects of chainsaw, circular saw, and grinding saw injuries in the maxillofacial region.

Konstantinović VS, Puzović D, Anicić B, Jelovac DB.

J Craniofac Surg. 2010 Jul;21(4):1029-32. doi: 10.1097/SCS.0b013e3181e432bd.

PMID:
20613565
28.

[Correlation between disease progression and histopathologic criterions of the lip squamous cell carcinoma].

Golubović M, Asanin B, Jelovac D, Petrović M, Antunović M.

Vojnosanit Pregl. 2010 Jan;67(1):19-24. Serbian.

PMID:
20225630
29.
30.

Aromatase and breast cancer.

Brodie A, Sabnis G, Jelovac D.

J Steroid Biochem Mol Biol. 2006 Dec;102(1-5):97-102.

31.

Docetaxel followed by castration improves outcomes in LNCaP prostate cancer-bearing severe combined immunodeficient mice.

Tang Y, Khan MA, Goloubeva O, Lee DI, Jelovac D, Brodie AM, Hussain A.

Clin Cancer Res. 2006 Jan 1;12(1):169-74.

32.

The ErbB3-binding protein Ebp1 suppresses androgen receptor-mediated gene transcription and tumorigenesis of prostate cancer cells.

Zhang Y, Wang XW, Jelovac D, Nakanishi T, Yu MH, Akinmade D, Goloubeva O, Ross DD, Brodie A, Hamburger AW.

Proc Natl Acad Sci U S A. 2005 Jul 12;102(28):9890-5. Epub 2005 Jun 30.

33.

Model systems: mechanisms involved in the loss of sensitivity to letrozole.

Brodie A, Jelovac D, Sabnis G, Long B, Macedo L, Goloubeva O.

J Steroid Biochem Mol Biol. 2005 May;95(1-5):41-8.

PMID:
15967659
34.

Additive antitumor effect of aromatase inhibitor letrozole and antiestrogen fulvestrant in a postmenopausal breast cancer model.

Jelovac D, Macedo L, Goloubeva OG, Handratta V, Brodie AM.

Cancer Res. 2005 Jun 15;65(12):5439-44.

35.

Activation of mitogen-activated protein kinase in xenografts and cells during prolonged treatment with aromatase inhibitor letrozole.

Jelovac D, Sabnis G, Long BJ, Macedo L, Goloubeva OG, Brodie AM.

Cancer Res. 2005 Jun 15;65(12):5380-9.

36.
37.

Therapeutic observations in MCF-7 aromatase xenografts.

Brodie A, Jelovac D, Macedo L, Sabnis G, Tilghman S, Goloubeva O.

Clin Cancer Res. 2005 Jan 15;11(2 Pt 2):884s-8s. Review.

38.

Potent CYP17 inhibitors: improved syntheses, pharmacokinetics and anti-tumor activity in the LNCaP human prostate cancer model.

Handratta VD, Jelovac D, Long BJ, Kataria R, Nnane IP, Njar VC, Brodie AM.

J Steroid Biochem Mol Biol. 2004 Oct;92(3):155-65.

PMID:
15555909
39.

Effects of exemestane and tamoxifen in a postmenopausal breast cancer model.

Jelovac D, Macedo L, Handratta V, Long BJ, Goloubeva OG, Ingle JN, Brodie AM.

Clin Cancer Res. 2004 Nov 1;10(21):7375-81.

40.

Effects of the antiestrogen tamoxifen and the aromatase inhibitor letrozole on serum hormones and bone characteristics in a preclinical tumor model for breast cancer.

Núñez NP, Jelovac D, Macedo L, Berrigan D, Perkins SN, Hursting SD, Barrett JC, Brodie A.

Clin Cancer Res. 2004 Aug 15;10(16):5375-80.

41.

Therapeutic strategies using the aromatase inhibitor letrozole and tamoxifen in a breast cancer model.

Long BJ, Jelovac D, Handratta V, Thiantanawat A, MacPherson N, Ragaz J, Goloubeva OG, Brodie AM.

J Natl Cancer Inst. 2004 Mar 17;96(6):456-65.

PMID:
15026471
42.

The ceramide analog, B13, induces apoptosis in prostate cancer cell lines and inhibits tumor growth in prostate cancer xenografts.

Samsel L, Zaidel G, Drumgoole HM, Jelovac D, Drachenberg C, Rhee JG, Brodie AM, Bielawska A, Smyth MJ.

Prostate. 2004 Mar 1;58(4):382-93.

PMID:
14968439
43.

The relationship between aromatase in primary breast tumors and response to treatment with aromatase inhibitors in advanced disease.

de Jong PC, Blankenstein MA, Nortier JW, Slee PH, van de Ven J, van Gorp JM, Elbers JR, Schipper ME, Blijham GH, Thijssen JH, Lu Q, Jelovac D, Brodie AM.

J Steroid Biochem Mol Biol. 2003 Nov;87(2-3):149-55.

PMID:
14672735
44.

The intratumoral aromatase model: studies with aromatase inhibitors and antiestrogens.

Brodie AH, Jelovac D, Long B.

J Steroid Biochem Mol Biol. 2003 Sep;86(3-5):283-8.

PMID:
14623522
45.

Predictions from a preclinical model: studies of aromatase inhibitors and antiestrogens.

Brodie A, Jelovac D, Long BJ.

Clin Cancer Res. 2003 Jan;9(1 Pt 2):455S-9S.

Supplemental Content

Loading ...
Support Center